In this study, we tested whether cardiac PAOs accumulate in acquired HF and whether pSer31 (Ser31 phosphorylated)-mimetic desmin promotes the formation of PAOs in cardiac myocytes. Further, we devised new protocols to track the build-up of PAOs in vitro and in vivo. To this end, we optimized a new method to purify, measure, and characterize amyloid in-gel, tested the effectiveness of a small molecule in reducing these species in vitro, and measured the build-up of cardiac PAOs in acquired HF in vivo by the unprecedented use of positron emission tomography (PET).
Methods
The data and methods supporting the findings in the article are available from the corresponding author on reasonable request.
Animal and Cellular Models and Human Myocardial Tissue
Transverse aortic constriction (TAC) and echocardiography were performed as previously described and in accordance with institutional guidelines.
14 Human myocardial tissue samples were obtained as described previously, under protocols approved by the Institutional Review Boards at the University of Pennsylvania (PA, USA) and Johns Hopkins University (MD, USA). 15 Neonatal rat ventricular myocytes isolation and lentiviral vectors production and infection were performed as described previously by Sekar et al. 16 Details are provided in the Online Data Supplement.
Protein Biochemistry
Protein extraction, Western blot analysis, and mass spectrometry (MS) were performed as described previously 1 with minor modifications described in the Online Data Supplement.
Live Cell Imaging
Living cells expressing desmin-GFP (green fluorescent protein) phosho-null/mimetic mutants were imaged using a spinning disc inverted confocal microscope equipped with 2 high-speed cameras (Olympus/ Andor Revolution). Videos of living cells were acquired at a ×40 magnification. Software-assisted image analysis was performed using the Image J package, Fiji.
Filter Assay
A filter assay to trap amyloid aggregates was used as we described, 9 with some modifications described in the Online Data Supplement.
PET and Single-Photon Emission Computed Tomography
Please refer to the Online Data Supplement for details regarding PET and single-photon emission computed tomography.
Statistical Analysis
Data were normalized to the average of controls to correct for interexperimental variability when appropriate. In this case, data were expressed as percentage arbitrary units (AU%). Student t test was applied for the comparison of 2 experimental groups, whereas 1-way ANOVA followed by Tukey post hoc was used for the comparison of 3 groups. Statistical analyses were conducted using Prism 6 for Mac OS X (version 6.b). All data are displayed as mean values±SD.
Results

Desmin and PAOs Comigrate in Experimental Acquired HF
We previously reported the accumulation of cardiac PAOs in canine dyssynchronous HF, 1 suggesting that these species can accumulate in the presence of cardiac, mechanical stress. 
Novelty and Significance
What Is Known?
• Preamyloid oligomers (PAOs), similar to those observed in the brain of patients with Alzheimer and Parkinson diseases, accumulate in human heart failure (HF).
• PAOs are toxic to isolated cardiac myocytes, and they cause HF in transgenic mouse models.
• The mechanisms of cardiac PAOs formation in acquired (nongenetic) forms of HF are unclear.
What New Information Does This Article Contribute?
• Using a dual immunostaining approach and a novel in-gel staining for amyloid coupled with mass spectrometry, we show that cardiac PAOs and short fibrils containing the cytoskeletal protein desmin accumulate in murine and human acquired HF.
• The small-molecule epigallocatechin gallate is able to deaggregate cardiac PAOs and short fibrils in vitro.
• Positron emission tomography is able to detect the increased levels of cardiac amyloid in murine acquired HF in vivo, in a noninvasive fashion.
HF represents the common end stage of several cardiac morbidities and is on the rise. The mechanisms underlying the transition from compensated left ventricle hypertrophy to maladaptive cardiac remodeling and failure remain ill defined. The observation that many forms of HF share impaired proteostasis, regardless of their cause, highlights the pivotal role of protein misfolding in this transition. Although protein mutations trigger the deposition of cardiac amyloid, our data suggest that a modified form of the cytoskeletal protein desmin acts as a nucleating seed in the formation of toxic PAOs in the heart, in the absence of any genetic mutation. We used new methodologies and optimized existing ones to specifically and accurately detect PAOs ex vivo and in vivo. Importantly, we report that epigallocatechin gallate can deaggregate cardiac amyloid in vitro.
whether cardiac accumulation of PAOs occurs with acquired forms of HF, we used TAC, one of the best established experimental models of HF. 17 Four weeks after TAC, mice developed eccentric cardiac hypertrophy and overt HF as documented by heart weight, lung congestion, and echocardiography (Online Table I ). We then combined Western blot analysis with infrared fluorescence imaging (LI-COR) to simultaneously measure PAOs levels and their juxtaposition with desmin ( Figure 1 ). The A11 antibody used here detects PAOs generated by different amyloidogenic sequences, such as Aβ, α-synuclein, prions, and others. 18 Because the only other common feature among these species is toxicity, the antibody recognizes an epitope responsible for their toxicity (=toxic epitope). 18 We first detected the concurrent increase in the formation of PAOs and desmin cleavage in TAC mice versus controls (≈2.5-fold; P=0.0006 and ≈2-fold; P=0.006, respectively, Figure 1A through 1C). We also found that wild-type (WT) desmin coenriches and comigrates with PAOs in this model ( Figure 1A ) and confirmed desmin cleavage by MS (Online Figure I) .
Desmin Cardiac PAOs Accumulate in Human HF
To address the clinical relevance of these findings, we tested whether PAOs accumulate in human bioptic samples from dilated (nonischemic, dilated cardiomyopathy; Figure 1D through 1F) and ischemic cardiomyopathy ( Figure 1G through 1I). Using Figure 1 . Desmin preamyloid oligomers (PAOs) accumulate in experimental and human heart failure (HF). PAOs (green, A11) and desmin (des, red) detected by Western blot analysis: PAOs comigrated with desmin in myofilament-enriched protein homogenates from transverse aortic constriction (TAC) mouse hearts (A). Densitometry highlighted a ≈2.5-fold increase in PAOs (P=0.0006; n=6 each; B) and a ≈2-fold increase in desmin cleavage (P=0.006; n=4 each; C) in TAC vs sham control (Ctrl) mice. An ≈2-fold increase of both desmin PAOs (P=0.0366; n=5 each; D and E) and desmin cleavage (P=0.0270; n=5 each; F) was also observed in dilated (nonischemic) cardiomyopathy (DCM) compared with nonfailing (NF) human hearts. An ≈3-fold increase in the A11 signal at ≈190 kDa, compatible with short fibrils, was evident in ischemic cardiomyopathy (ICM) patients compared with NF controls (P=0.00164; n=5/4 each; G and H), along with a ≈4-fold increase in desmin cleavage (P=0.0691; n=5/4 each; I). An image of the total protein stain by direct blue 71 (DB71, Sigma) is also provided for every blot. AU indicates arbitrary units.
the same double-staining approach, we confirmed a ≈2-fold increase of both cardiac desmin PAOs (P=0.0366; Figure 1E ) and desmin cleavage (P=0.0270; Figure 1F ) in dilated cardiomyopathy patients compared with nonfailing controls. Intriguingly, our approach was able to differentiate dilated cardiomyopathy from ischemic cardiomyopathy patients. In fact, a ≈3-fold increase in the A11 signal at ≈190 kDa (compatible with short fibrils, see below) but not 55 kDa, was observed in ischemic cardiomyopathy patients compared with controls (P=0.00164; Figure 1H ), along with a ≈4-fold increase in desmin cleavage (P=0.0691; Figure 1I ). These data suggest that, although amyloid accumulation may represent a common denominator in different types of acquired, human HF, it is possible that the mechanisms and dynamics of their formation may vary. Follow-up studies that include a larger sample size are warranted to generalize the validity of these findings.
Epigallocatechin Gallate Deaggregates WT Desmin PAOs in Proteotoxic HF
To allow direct, downstream MS, we developed a novel staining approach based on a widely used histological stain for amyloid, Thioflavin T (ThT), 1 and optimized it for classical, reducing SDS-PAGE (Figure 2A and 2B) . We first validated the robustness of the method using cardiac extracts from R120G cryAB mice, a well-established model of cardiac proteotoxicity. The native desmin sequence is conserved and Pattison et al 19 demonstrated a causal relationship between PAOs and HF development in these animals. Using our new in-gel stain, we detected an ≈5-fold increase in the ThT-positive signal compatible with desmin (P=0.0005). The specificity of the staining was confirmed by an ≈50% decrease in the fluorescent signal on treatment of the cardiac extracts with 20 μmol/L epigallocatechin gallate (EGCG; Figure 2B ; P=0.0196), which disrupts amyloid species.
1,20 Lastly, we confirmed desmin's presence in the ThT-positive bands by MS (Online Figure II) . Taken together, these findings suggest that in a model of proteostasis insufficiency, where desmin's main chaperone is mutated while its native sequence is conserved, WT desmin contributes to the generation of PAOs. It is likely that other players and mechanisms contribute to the generation of PAOs, and we cannot exclude that desmin loss Densitometry revealed a ≈5-fold increase in a ThT-positive band at ≈55 kDa in R120G cryAB samples compared with NTG controls (P=0.0005; n=6 each). EGCG treatment resulted in a ≈50% reduction in amyloid, ThT-positive signal (P=0.0196; n=6 each; B). The same samples were analyzed by Western blot using dual staining for PAOs (green) and desmin (des, red; C). Densitometry revealed an ≈9-fold increase in desmin PAOs (P=0.0003; n=7/5 each; C and D) and a relative increase of ≈28-fold in desmin cleavage compared with intact desmin (n=7/5 each; E and F). Lastly, a ≈9-fold increase in cryAB was observed in R120G vs NTG (P=0.0137; n=7/5 each; G and H), although this signal did not overlap with that of desmin (or hence its PAOs). An image of the total protein stain by direct blue 71 (DB71, Sigma) is also provided for every blot. AU indicates arbitrary units; and CBB, Coomassie brillant blue.
of function could play an important role in the process. These aspects will be addressed in follow-up studies. Regardless of the relative contribution of desmin gain versus loss of function to the process, we think that, the effectiveness of EGCG in reducing the levels of amyloid in vitro opens new avenues for the therapeutic assessment of this and other small molecules for HF patients.
We further confirmed the increase of desmin PAOs (≈9-fold; P=0.0003; Figure 2C and 2D) in the same proteotoxic model (R120G cryAB mice) using the dual immunostaining approach described above. When compared with nontransgenic controls, these mice display amplified desmin cleavage, and the resulting fragment disproportionally increases (≈28-fold) with respect to intact desmin ( Figure 2E and 2F) . The A11 and the anti-cryAB antibodies are both raised in rabbit and, therefore, cannot be used jointly. We detected a faint A11 signal compatible with cryAB's molecular weight, which was upregulated in R120G cryAB mice (data not shown). However, using the antidesmin antibody as a reference, we show that cryAB does not seem to directly participate in the formation of desmin cardiac PAOs ( Figure 2G and 2H ).
Phosphorylation at Ser31 Promotes Desmin Aggregation
We previously reported the accumulation of monophosphorylated cardiac desmin and characterized the first 2 phosphosites (Ser-27 and -31) in canine and human HF. 1 The 2 sites are part of a consensus sequence for GSK3-β (glycogen synthase kinase 3-β), a kinase that classically recognizes a phosphorylated substrate (eg, pSer31) and phosphorylates a residue 3 amino acids upstream (eg, Ser-27). We also reported that GSK3-β phosphorylates desmin in vitro 1 and know that GSK3-β is inhibited in canine dyssynchronous HF. 21 Therefore, we hypothesized that GSK3-β inhibition in HF leads to the accumulation of amyloidogenic pSer31 desmin. Consequently, if the biphosphorylated form is the physiological proteoform, it should be less prone to aggregation. 1 To test these hypotheses, we created bi-and mono-phosphomimetic desmin double mutants using site mutagenesis and overexpressed them in neonatal rat ventricular myocytes using lentiviral vectors expressing cytomegalovirus-driven and GFP-fused bi-and mono-phospho-mimetic desmin double mutants (S27D, S31D, or DD; and S27A, S31D, or AD). We found that in transduced cells, exogenous desmin accounts for ≈25% of total desmin (Online Figure III) , which well reflects the stoichiometry of phospho-desmin proteoforms in clinical samples. 1 We then examined transduced cells by live imaging using confocal, spinning disk microscopy to measure the proportion of contracting cells and desmin incorporation at the Z-bands. Expression of the desmin double phosphomimetic mutant (DD) resulted in the highest number of contracting cells after 1 week in culture (P=0.032 versus WT and P=0.0012 versus AD; Figure 3A ). This behavior was mirrored by the highest degree of desmin incorporation at the Z-bands (P=0.0001 versus WT and P=0.0005 versus AD; Figure 3B and 3C). In keeping with our proposed model, this evidence suggests that the doubly phosphorylated form is the physiological proteoform. Similarly, expression of pSer31 obligatory monophospho-mimetic desmin (AD) resulted in decreased Z-bands incorporation ( Figure 3B) , as well as an increased formation of desmin-positive aggregates by filter assay, indicating that this is a pathological proteoform (P=0.012; Figure 3D and 3E). ThT staining (newly combined here with the filter assay) independently confirmed the increased propensity of pSer31 desmin to aggregate ( Figure 3E) . Interestingly, the average frequency of spontaneous contraction in pSer31-mimetic cells was 21% to 48% elevated in these mutants compared with the other groups (DD, P=0.0002 and WT, P<0.0001, respectively; Online Figure IVA) . We interpret this observation as a dysregulation of ion fluxes, in agreement with the known permeabilizing effect of reconstituted PAOs on isolated cardiac cells.
2,22 Lastly, we used magnetic twist cytometry on isolated neonatal rat ventricular myocytes to assess whether desmin PTMs and aggregation result in a loss of function impacting cytoskeletal stability and cell biophysics. We found no significance difference in cell stiffness in pSer31-mimetic (AD) and double phospho-mimetic (DD) mutants compared with WT, suggesting that loss of desmin function has no discernible contribution to the adverse phenotype observed in pSer31-mimetic mutants (Online Figure IVB) .
Desmin Amyloid Is Increased and Detectable in Pressure-Overload HF In Vivo
PET-computed tomography is increasingly recognized as a viable alternative to invasive biopsies to diagnose genetic cardiac amyloidosis, 23, 24 but to our knowledge, it was never used to measure cardiac amyloid deposition in nongenetic HF before. Therefore, we used PET imaging for the unprecedented assessment of the accumulation of cardiac PAOs in vivo, in acquired HF. Notably, most of the tracers being investigated for the noninvasive, early detection of PAOs accumulation in Alzheimer and Parkinson diseases 25 are chemical derivatives of ThT. This chemical homology allowed us to correlate our PET data with those from the ThT in-gel stain assay.
To test our hypothesis that PAOs are formed in acquired HF in vivo, we injected 4-week TAC and sham-operated mice each with 200 μCi of ( 18 F) Amyvid and imaged them using PET-computed tomography. We found a significant, 13±4.2% increase in ( 18 F) Amyvid cardiac uptake in TAC mice compared with sham controls (P=0.0194), confirming the ex vivo data on increased PAOs accumulation in HF ( Figure 4A and 4B). There were no differences in regional perfusion as determined by the single-photon emission computed tomography Figure 4 . Amyloid accumulation in pressure-overload heart failure (HF) as detected noninvasively by positron emission tomography (PET) and ex vivo by Thioflavin T (ThT) in-gel stain. Four-week transverse aortic constriction (TAC) mice and sham controls were injected with the amyloid PET-tracer amyvid and imaged by PET. Representative images of the tracer signal, superimposed on computed tomography scans are provided (A top). The single-photon emission computed tomography (SPECT) tracer Cardiolite was used to rule out difference in myocardial blood flow. Normalized amyvid uptake was analyzed (n=8 each; A bottom). Normalized cardiac uptake of Amyvid is plotted in B. ThT in-gel stain confirmed an ≈3-fold increase in short, fibrillar amyloid ex vivo (P=0.0005; n=6 each; C). The presence of desmin in these bands was confirmed by mass spectrometry (Online Figure V) . An ≈21% decrease in the ThT signal on treatment with epigallocatechin gallate (EGCG) confirmed the specificity of the stain (C and D) . AU indicates arbitrary units; CBB, coomassie brillant blue; and Ctrl, control.
tracer Cardiolite, ruling out increased Amyvid uptake because of differences in regional myocardial blood flow ( Figure 4A) . Because of the chemical similarity between Amyvid and ThT, it is likely that the tracer identifies the same desmin PAOs and short fibrils that we detected with our ThT in-gel stain.
Indeed, when we analyzed cardiac extracts from TAC mice and controls, a ThT-positive band was increased in TAC mice myocardia versus controls (≈3-fold; P=0.0005) and reduced on treatment with EGCG (≈21%; P=0.246; Figure 4C and 4D) . We confirmed the presence of desmin in this band, which is compatible with short fibrils, by MS (Online Figure V) .
This evidence, combined with the data on the amyloydogenic potential of pSer31-mimetic desmin, supports the notion that post-translationally modified desmin acts as the seed for the nucleation of cardiac PAOs in acquired HF in vivo, as well as the potential diagnostic applications of our findings.
Discussion
Our study demonstrates that cardiac desmin PAOs accumulate in murine, pressure-overload-induced, and human HF. Combined with the marked accumulation of desmin PAOs in a model of chaperone insufficiency (R120G cryAB mice), these data suggest that desmin PTMs, much like protein mutations, facilitate misfolding of desmin in the failing heart. This hypothesis draws further support from the present data showing that pSer31 phospho-mimetic desmin has an increased propensity to aggregate and that this is toxic for isolated cells. This study also allowed us to refine our newly developed ingel stain for amyloid and first combining ThT with a filter assay to confirm the amyloid nature of protein aggregates separated with these methods. From the translational standpoint, we provide proof of concept on the efficacy of EGCG in deaggregating amyloid in pressure-overload-induced and proteotoxic HF. Furthermore, we successfully measured the accumulation of PAOs in a well-established experimental model of acquired HF (TAC), noninvasively, using PET-computed tomography for the first time. Therefore, PET could constitute a viable, noninvasive tool to monitor PAOs formation, as well as their potential therapeutic reduction in acquired HF, in vivo.
Desmin is the major component of intermediate filaments (IFs) in cardiac myocytes. 26 Unlike the other components of the cytoskeleton (mictrotubules and actin filaments), IFs are constituted by distinct proteins in different cell types, which arguably hampered the creation of a unified vision on their function. In muscle cells, IFs have classically been viewed as mere scaffolds, maintaining sarcomeric alignment and the relative positioning of different organelles. 27, 28 However, recent studies report numerous new functions for IFs in different cells types, including cardiac myocytes. 26, 29, 30 The general consensus is that IFs were selected by evolution to confer protection against acute, mechanical stress in multicellular organisms without an exoskeleton. We propose that in the heart, this advantage came at a cost that is revealed under extended chronic stress: the formation of toxic PAOs. We and others demonstrated the accumulation of PAOs in clinical and experimental HF. [1] [2] [3] [4] [5] 22 However, the modality of formation of these species in the heart is unknown to date and unlike other established proteinopathies (Alzheimer, Parkinson, etc), the seed that initiates the nucleation process leading to cardiac PAOs formation remains the object of debate in acquired forms of HF. 6 The only mechanistic studies to our knowledge include that of Subramanian et al, 5 who recently demonstrated the accumulation of cofilin-2-or presenilin-positive PAOs in subsets of idiopathic dilated cardiomyopathy patients, 2 and work from Despa et al 22 reporting amylin PAOs in models of diabetic cardiomyopathy. Here, we demonstrate that experimental, nongenetic models such as pressure-overload and human ischemic and nonischemic HF share the accumulation of desmin PAOs. In light of the evolutionary role played by IFs in response to stress, it is tempting to speculate that the formation of desmin PAOs may represent a general mechanism of adaptation to cardiac overload. Light-chain and TTR (transthyretin) amyloidosis (AL and ATTR, respectively) are 2 notorious examples of genetic cardiac amyloidosis where the mutation of a protein sequence or its overproduction trigger the massive accumulation of cardiac amyloid. 31 Although both are systemic amyloidosis, one of the organs that is most affected and usually determines prognosis is the heart. 31 WT TTR also generates amyloid in the aging heart, in what was formerly known as cardiac senile amyloidosis and is now referred to as WT TTR amyloidosis (ATTRwt). The discovery that PTMs (eg, oxidative) modulate the propensity of WT TTR and its genetic variants to aggregate provides a potential explanation of why amyloid accumulates later in life 32 and corroborates our theory on the contribution of toxic PTMs, rather than genetic mutations, to cardiac protein misfolding. 1, 6, 9 The recent technological advances in the field of MS have unveiled a mind-blowing heterogeneity of protein PTMs. 27 There are currently ≈500 different types of PTMs listed in protein databases resulting from either chemical (eg, oxidation) or enzymatic (eg, phosphorylation) reactions. 6 These 2 classes of PTMs modulate protein misfolding and are respectively sustained by physical factors such as exceedingly oxidative or reductive environments and chronic imbalance of signaling pathways, all of which are well documented in HF and other proteinopathies. 6 Therefore, we think that the elucidation of the pathophysiological role of protein PTMs will greatly help our understanding of the molecular mechanisms underlying HF development.
Various evidence points to a protective role of EGCG in cardiovascular and neurodegenerative diseases. [33] [34] [35] Our data on the ability of EGCG in deaggregating cardiac amyloid in vitro provide a new interpretation for the protective effects of polyphenols. Therefore, we think that molecules that directly target cardiac PAOs formation could be of therapeutic value for HF patients. In fact, our new use of PET to measure cardiac PAOs noninvasively in acquired forms of HF demonstrates that PAOs are not artifacts because of protein extraction. From a translational standpoint, this exciting new application enables future studies addressing the temporal association between PAOs accumulation and cardiac dysfunction in vivo, as well as studies testing its diagnostic and prognostic applicability.
In conclusion, we report that desmin cleavage and phosphorylation contribute to the formation of cardiac aggregates and PAOs. WT desmin generates PAOs in murine and human HF. Combined with the increased propensity of pSer31 desmin to aggregate, this new evidence supports a model where monophosphorylated and potentially cleaved desmin is the seed priming the nucleation process that leads to the formation
